IONIS-PKKRx / Ionis - LARVOL DELTA

Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies. (PubMed, Expert Opin Investig Drugs) - "ATN-249 is an oral drug that has shown promising results in preclinical and Phase I studies, and good tolerability in the prophylactic treatment of attacks. KVD900 is also an oral agent developed for the on-demand treatment of HAE attacks...The third drug, IONIS-PKKRx, is an antisense oligonucleotide targeting plasma prekallikrein mRNA...STAR-0215 is a long acting anti-activated kallikrein monoclonal antibody...Lastly, NTLA-2002 is an investigational gene-editing therapy. The targeted treatment of the dysregulated kinin-kallikrein system with specific inhibitors is promising for the prevention of angioedema attacks. Ongoing phase III studies will provide further insight into the efficacy and long-term safety of these novel therapies, potentially expanding treatment options for HAE treatment."

Journal • Preclinical • Review • Cardiovascular • Complement-mediated Rare Disorders • Genetic Disorders • Hereditary Angioedema

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine (clinicaltrials.gov) - P2; N=30; Completed; Sponsor: Smith, Timothy R., M.D.; N=43 ➔ 30

Clinical • Enrollment change

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine (clinicaltrials.gov) - P2; N=43; Completed; Sponsor: Smith, Timothy R., M.D.; Active, not recruiting ➔ Completed

Clinical • Trial completion

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine (clinicaltrials.gov) - P2; N=43; Active, not recruiting; Sponsor: Smith, Timothy R., M.D.; Trial completion date: Dec 2018 ➔ Jun 2019; Trial primary completion date: Dec 2018 ➔ Jun 2019

Clinical • Trial completion date • Trial primary completion date